Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Bevacizumab + Telatinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bevacizumab||Avastin||VEGF Antibody 11 VEGFR Inhibitor (Pan) 32||Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).|
|Telatinib||BAY 57-9352||KIT Inhibitor 51 PDGFR-beta Inhibitor 13 VEGFR2 Inhibitor 35 VEGFR3 Inhibitor 5||Telatinib (BAY 57-9352) inhibits VEGFR2, VEGFR3, PDGFR-beta (PDGFRB), and KIT, which may result in decreased proliferation and angiogenesis in tumors expressing these factors (PMID: 29511030).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Bevacizumab + Telatinib||Phase I||Actionable||In a Phase I trial, the combination of BAY 57-9352 (telatinib) with Avastin (bevacizumab) in patients with advanced solid tumors resulted in antitumor activity, but demonstrated increasing toxicity over time (PMID: 21378200).||21378200|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|